RN 0191
Alternative Names: RN-0191Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Ikaria Bioscience
- Class Antihyperlipidaemics
- Mechanism of Action PCSK9 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hypercholesterolaemia
Most Recent Events
- 18 Nov 2024 Adverse events and efficacy data from the phase I trial in Hyperlipidaemia released by Rona Therapeutics
- 16 Nov 2024 Updated adverse events data from a phase I trial in Hypercholesterolemia presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)
- 19 Jul 2024 Rona Therapeutics completes phase I trial in Hypercholesterolemia (In volunteers) in China (SC) (NCT06132360)